Reference health

Patent Duration, Breadth and Costly Imitation: Evidence from the US Pharmaceutical Market

https://doi.org/10.2139/ssrn.2753543
CiteStamped reference-health badge
25/25 checkable references clean · checked 2026-08-27

Every reference with a DOI in the deposited reference list resolved to a known work in Crossref or DataCite at the dated check, and none carried a retraction, withdrawal, or removal notice.

26 without a DOI — not checked. A reference deposited without a DOI is never matched by title or guessed at; it stays outside the checked set, and this line discloses that.

The 25 checked references that resolve
resolves10.2139/ssrn.1443412
Did TRIPS Spur Innovation? An Empirical Analysis of Patent Duration and Incentives to Innovate
resolves10.1162/0033553041502144
Market Size in Innovation: Theory and Evidence from the Pharmaceutical Industry
resolves10.1093/qje/120.2.701
Competition and Innovation: an Inverted-U Relationship
resolves10.1111/j.1756-2171.2009.00081.x
Sequential innovation, patents, and imitation
resolves10.2139/ssrn.831685
The Patent Litigation Explosion
resolves10.1257/jep.27.1.3
The Case Against Patents
resolves10.1257/aer.20131176
Do Firms Underinvest in Long-Term Research? Evidence from Cancer Clinical Trials
resolves10.2307/2950496
Patent Races and Optimal Patent Breadth and Length
resolves10.1111/j.1468-0327.2007.00188.x
Do patents over-compensate innovators?
resolves10.1257/aer.20141301
The Market Impacts of Pharmaceutical Product Patents in Developing Countries: Evidence from India
resolves10.1093/qje/qju029
Patents and Cumulative Innovation: Causal Evidence from the Courts *
resolves10.2307/2555432
Patent Policy and Costly Imitation
resolves10.2307/2555497
Optimal Patent Length and Breadth
resolves10.1086/662721
Waiting to Imitate: On the Dynamic Pricing of Knowledge
resolves10.2307/2555498
How Broad Should the Scope of Patent Protection Be?
resolves10.1162/rest_a_00214
Investments in Pharmaceuticals Before and After TRIPS
resolves10.1257/000282802320189294
150 Years of Patent Protection
resolves10.1257/aer.99.2.343
The Empirical Impact of Intellectual Property Rights on Innovation: Puzzles and Clues
resolves10.1016/j.jeconom.2007.05.005
Manipulation of the running variable in the regression discontinuity design: A density test
resolves10.1111/1468-0335.00299
The Independent Invention Defence in Intellectual Property
resolves10.1257/jep.27.1.23
Patents and Innovation: Evidence from Economic History
resolves10.2307/2696399
Do Stronger Patents Induce More Innovation? Evidence from the 1988 Japanese Patent Law Reforms
resolves10.3386/w21666
How Do Patents Affect Follow-On Innovation? Evidence from the Human Genome
resolves10.1198/073500102288618658
A Survey of Weak Instruments and Weak Identification in Generalized Method of Moments
resolves10.1007/bf01234644
Innovation and imitation under imperfect patent protection
The 26 references without a DOI — listed, not checked
no DOI — not checkedref7
no DOI — not checkedref9
no DOI — not checkedref10
no DOI — not checkedref13
no DOI — not checkedCompetition between generic and branded drugs
no DOI — not checkedThe distribution of sales revenues from pharmaceutical innovation
no DOI — not checkedWhen do generics challenge drug patents?
no DOI — not checkedEarning Exclusivity: Generic Drug Incentives and the Hatch-Waxman Act
no DOI — not checkedref23
no DOI — not checkedref26
no DOI — not checkedCharacteristics of patent litigation: A window on competition
no DOI — not checkedLanjouw and Mark Schankerman Patent Quality and Research Productivity: Measuring Innovation with Multiple Indicators
no DOI — not checkedExaminer characteristics and patent oce outcomes
no DOI — not checkedref35
no DOI — not checkedThe optimum life of a patent: Reply
no DOI — not checkedref37
no DOI — not checkedref38
no DOI — not checkedref41
no DOI — not checkedref42
no DOI — not checkedThe US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research. Guidance for industry -180-day exclusivity when multiple ANDAs are submitted on the same day
no DOI — not checkedFood and Drug Administration, Center for Drug Evaluation and Research. Guidance for industry -Listed drugs, 30-month stays, and approval of ANDAs and 505(b)(2) applications under HatchWaxman, as amended by the Medicare Prescription Drug, Improvement, and Modernization Act of
no DOI — not checkedOn the optimal patent policy
no DOI — not checkedRevitalizing the patent system to incentives pharmaceutical innovation: the potential claims with means-plus-function clauses
no DOI — not checkedThe economics of product patents
no DOI — not checkedGeneric competition and pharmaceutical innovation: The Drug Price Competition and Patent Term Restoration Act of 1984
no DOI — not checkedref51
What this badge says. CiteStamped means the CHECKABLE references of this work were clean at the dated check: each resolved to a known work in a public registry, and none carried a retraction notice at that time. It says nothing about the quality, findings, or importance of the work itself, and nothing about references deposited without a DOI.

checked 2026-08-27 — re-checked daily as this page is visited; titles and statuses come from Crossref and DataCite and are not part of the signed record

Embed this badge

Both snippets point at the live badge image and link back to this page. The badge re-renders from the daily check, so an embed never goes stale by more than a day of visits.

<a href="https://citestamp.com/citestamped/10.2139/ssrn.2753543"><img src="https://citestamp.com/citestamped/10.2139/ssrn.2753543/badge.svg" alt="CiteStamped reference-health badge" width="460" height="64"></a>
[![CiteStamped reference-health badge](https://citestamp.com/citestamped/10.2139/ssrn.2753543/badge.svg)](https://citestamp.com/citestamped/10.2139/ssrn.2753543)